Rapid relapse after stopping paliperidone did not look like a withdrawal effect

Design

Individual participant data meta-analysis of five randomised, double-blind discontinuation trials

Population

417 people with schizophrenia or schizoaffective disorder who relapsed in paliperidone trials

Primary outcome

Relapse trajectory and its association with discontinuation

Effect

Rapid relapse 20% vs 11% (LAI, p=0.12) and 27% vs 26% (oral, p=0.95), discontinuation vs continuation

Published in August, this analysis pooled individual participant data from five double-blind discontinuation trials of oral and long-acting injectable paliperidone. It examined 417 people with schizophrenia or schizoaffective disorder whose illness relapsed, either after switching to placebo or while continuing the drug.

Modelling of symptom scores before relapse found two trajectories: rapid and delayed. Rapid relapse was not over-represented among those who stopped the drug: in the injectable trials 20% of discontinuers versus 11% of continuers relapsed rapidly (p=0.12), and in the oral trials 27% versus 26% (p=0.95). Symptom profiles at relapse did not differ by whether the drug had been stopped. People with rapid relapse had higher baseline PANSS scores.

The finding argues against the idea that a fast relapse after stopping is usually a pharmacological rebound rather than the illness returning. That matters when deciding whether a person who relapsed quickly after a trial off medication might do better with a slower taper. The data come from one drug and from trial populations, so the result may not extend to clozapine or to abrupt stops of high-potency agents.

• Treat a rapid relapse after stopping an antipsychotic as likely illness return, not simply rebound.
• Record baseline symptom severity before any dose reduction, since higher severity was linked to rapid relapse.
• Agree an early-warning plan with the patient and family before deprescribing.
• Arrange closer review in the first weeks after a reduction for patients with more severe residual symptoms.

Why it matters

It challenges the common assumption that quick relapse after stopping is a withdrawal phenomenon that a slower taper would have prevented.

Don't overread it

This covers paliperidone in trial populations only, and does not show that tapering speed is irrelevant.

The statistics, in plain English

The injectable-trial gap of 20% versus 11% looks large, but with only 74 continuers it could easily be chance (p=0.12). A non-significant difference is not proof of no difference; it means this dataset could not detect one. The oral trials showed almost identical rates.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.